Reumatología

2021

1. AB0771 High Dose Intravenous Methylprednisolone Induces Rapid Improvement of Visual Acuity in Non-Infectious Uveitis of Different Immune Mediated Inflammatory Diseases

   Annals of the Rheumatic Diseases, Vol. 80, Núm. Suppl 1, pp. 1412.1-1412

2. Abatacept in monotherapy vs combined in interstitial lung disease of rheumatoid arthritis-multicentre study of 263 Caucasian patients

   Rheumatology (Oxford, England), Vol. 61, Núm. 1, pp. 299-308

3. BAFF, APRIL and BAFFR on the pathogenesis of Immunoglobulin-A vasculitis

   Scientific Reports, Vol. 11, Núm. 1

4. Body mass index and disease activity in chronic inflammatory rheumatic diseases: Results of the cardiovascular in rheumatology (CARMA) project

   Journal of Clinical Medicine, Vol. 10, Núm. 3, pp. 1-10

5. Clinical factors associated with discontinuation of ts/bDMARDs in rheumatic patients from the BIOBADASER III registry

   Scientific Reports, Vol. 11, Núm. 1

6. Clinical remission and subsequent relapse in patients with juvenile idiopathic arthritis: predictive factors according to therapeutic approach

   Pediatric Rheumatology, Vol. 19, Núm. 1

7. Combined use of QRISK3 and SCORE as predictors of carotid plaques in patients with rheumatoid arthritis

   Rheumatology (Oxford, England), Vol. 60, Núm. 6, pp. 2801-2807

8. Contributions of the lupus register of the Spanish Society of Rheumatology (RELESSER) to the knowledge of systemic lupus erythematosus in Spain

   Reumatologia Clinica, Vol. 17, Núm. 5, pp. 245-249

9. Cost-Effectiveness of Therapeutic Drug Monitoring-Guided Adalimumab Therapy in Rheumatic Diseases: A Prospective, Pragmatic Trial

   Rheumatology and Therapy, Vol. 8, Núm. 3, pp. 1323-1339

10. Disease activity influences the reclassification of rheumatoid arthritis into very high cardiovascular risk

    Arthritis Research and Therapy, Vol. 23, Núm. 1

11. Do all antiphospholipid antibodies confer the same risk for major organ involvement in systemic lupus erythematosus patients?

    Clinical and Experimental Rheumatology, Vol. 39, Núm. 3, pp. 555-563

12. Evaluation of the collaboration between Primary and Hospital Care in order to improve inappropriate prescription

    Journal of Healthcare Quality Research, Vol. 36, Núm. 2, pp. 91-97

13. Flare rate thresholds for patient assessment of disease activity states in Gout

    Journal of Rheumatology, Vol. 48, Núm. 2, pp. 293-298

14. HLA association with the susceptibility to anti-synthetase syndrome

    Joint Bone Spine, Vol. 88, Núm. 3

15. Influence of prognosis factors on the prescription of targeted treatments in rheumatoid arthritis: A Delphi survey

    Joint Bone Spine, Vol. 88, Núm. 4

16. Late-onset versus early-onset systemic lupus: characteristics and outcome in a national multicentre register (RELESSER)

    Rheumatology (Oxford, England), Vol. 60, Núm. 4, pp. 1793-1803

17. Long-term Follow-up and optimization of infliximab in refractory uveitis due to Behçet Disease: National study of 103 white patients

    Journal of Rheumatology, Vol. 48, Núm. 5, pp. 741-750

18. Moderate and high disease activity predicts the development of carotid plaque in rheumatoid arthritis patients without classic cardiovascular risk factors: Six years follow-up study

    Journal of Clinical Medicine, Vol. 10, Núm. 21

19. Potential relation of cardiovascular risk factors to disease activity in patients with axial spondyloarthritis

    Therapeutic Advances in Musculoskeletal Disease, Vol. 13

20. Prevalence of symptomatic osteoarthritis in Spain: EPISER2016 study

    Reumatologia Clinica, Vol. 17, Núm. 8, pp. 461-470